A survey was carried out on a large family presenting the symptoms of familial arteriopathy (CADASIL) recently mapped to chromosome 19. This is characterised clinically by recurrent subcortical infarcts developing into pseudobulbar palsy and subcortical dementia, and radiologically by early MRI abnormalities.
Abstract
A survey was carried out on a large family presenting the symptoms of familial arteriopathy (CADASIL) recently mapped to chromosome 19. This is characterised clinically by recurrent subcortical infarcts developing into pseudobulbar palsy and subcortical dementia, and radiologically by early MRI abnormalities.
To characterise this familial condition, 43 members older than 20 years and spreading over four generations were studied clinically (31 living, 12 deceased), genetically, and radiologically by MRI (n = 31).
Twenty out of 43 were found to be clinically symptomatic and of these 13 out of 31 had MRI abnormalities. Genetic studies mapped this condition to the locus of CADASIL (lod score > 3). The natural history suggests a chronological clinicoradiological staging of this phenotype of CADASIL: stage I between 20 and 40 years with frequent migraine-like episodes and well delineated lesions of the white matter; stage II between 40 and 60 years with stroke-like episodes, bipolar or monopolar-like psychotic disorders, coalescent lesions of the white matter, and well delineated lesions of the basal ganglia; and stage III over 60 years with subcortical dementia, pseudobulbar palsy, diffuse leukoencephalopathy, and multiple well delineated lesions of the basal ganglia.
This phenotype differs from the other two previously described by high frequency of migraine, frequency of psychotic disorders, and early neurological manifestations. Figure 1 Family pedigree. Filled symbols = patients; empty symbols = healthy subjects; ()= possibly affected subjects; ? = unknown status; small symbols = subjects younger than 20 years; squares = male subjects; circles = female subjects; oblique slash = deceased; upper left = age at MRI examination. Subjects married into the family and subjects aged less than 20 years are not reported (except for IV-2, whose brother IV-1 is affected). Verin, Rolland, Landgraf, Chabriat, Bompais, Michel, et al the 31 living members) or from medical files or history given by the family (for the 12 deceased members). The 31 living subjects were genetically and radiologically studied after giving their informed consent. For ethical reasons, all the subjects were more than 20 years old.
The status of the living non-consenting members (n = 10) was considered as unknown. Wisconsin card sorting test, suggesting prefrontal dysfunction. We saw neither apraxia, agnosia, nor aphasia. Global intellectual efficiency was roughly preserved (Folstein's mini mental status = 27/30). At this time, MRI investigations showed well delineated lesions of the basal ganglia, most predominant in the right lenticular nucleus, and coalescent lesions of the white matter (fig 3, A and B) . Six months later, we found a progressive extrapyramidal syndrome (akinesia and rigidity) in the absence of any neuroleptic treatment and a subcortical dementia (adynamia, apragma- We found 20 clinically affected members out of 43 (46-5 %, seven deceased studied from medical files or history given by the family and 13 alive studied by direct examination and MRI investigations) and one probably affected deceased member. All the 13 living members whose MRI investigations showed abnormalities were clinically symptomatic. without aura (III-19) evolving since the patient's teens. Figure 5 sums up the natural history of the disease, showing the frequency of the clinical symptoms in each age group (from 20 to 40 years; from 40 to 60 years; over 60 years). w Migraine-like episodes with or without aura (fulfilling International Headache Society criteria'2) seem to be the most frequent sign across all age groups. Acute deficits, either transient or continuous, and psychiatric disorders, including either bipolar (n = 2) or monopolar depressive (n = 5) psychotic symptoms, are the second most frequent signs between 40 and 60 years. Subcortical dementia >60 is the prominent clinical feature after 60 years.
normal. Arterial hypertension was found in only one patient (III-11). It had been found two years before the examination and was well controlled by angiotensin convertase inhibitor. In eight patients (40%), the onset of the disease occurred when the patient was in his or her teens, with frequent isolated headaches, resembling migraine without aura and fulfilling International Headache Society criteria.'2 In eight patients (40%), the disease began with acute neurological deficit followed by headache resembling migraine; three during their teens, three at 14 The recent mapping of a familial hemiplegic migraine'5 and an autosomal dominant migraine with MRI white matter abnormalities'6 to the same locus as CADASIL should be other arguments in favour of a relation between migraine and CADASIL. The frequency of strokes and subcortical dementia is, however, a common characteristic of the three phenotypes and other familial cerebral arteriopathies already described but not yet mapped to chromosome 19.4-9 Because of its high frequency of migraine, this particular subvariety of CADASIL, different from the basic phenotype23 but also from the other hereditary cerebral arteriopathies,4 9 might be better described by the new acronym CADASILM for "cerebral autosomal domi-nant arteriopathy with subcortical infarcts, leukoencephalopathy, and migraine".
Psychotic disorders were found in seven patients out of 20 (35%), as either bipolar depressive psychosis in two (29%) or monopolar depressive psychosis in five (71%). The relatively frequent occurrence of psychotic disorders in this phenotype of CADASIL raises two important and interrelated questions. Firstly, are these psychotic symptoms part of this genetic disease-that is to say, related directly to the genomic abnormality in chromosome 19? In this hypothesis, the gene of CADASIL would be a candidate gene for the study of familial forms of bipolar psychotic disorders.'7 Another hypothesis could be that the CADASIL gene and the gene of a bipolar psychotic affection are localised in the same part of chromosome 19 . Secondly, what is the role of the subcortical lesions, in particular those affecting the basal ganglia, in the emergence of psychiatric symptoms? Several neuroimaging studies have shown subcortical lesions in poststroke mood disorders, characterised by either depression or mania.'8 '9 A further prospective study which is underway, especially in young patients with few subcortical lesions, and a comparison of both the psychiatric and neuroradiological symptoms will soon help answer these questions.
The correlations that we found between the age of the patients, the appearance of the clinical symptoms, and the type of cerebral lesions shown by MRI, allow us to propose a chronological clinicoradiological staging that summarises the natural history of this phenotype. Stage I evolves from 20 to 40 years with migraine (with or without aura), and MRI investigations show well delineated lesions of the white matter (for example, patient IV-1). Stage II evolves between 40 and 60 years with strokes and/or transient ischaemic attacks and psychotic disorders, and MRI investigations show coalescent lesions of the white matter and well delineated lesions of the basal ganglia (for example, patient III-16). Finally, stage III evolves after 60 years with subcortical dementia, and MRI investigations show diffuse leukoencephalopathy and multiple well delineated lesions of the basal ganglia (for example, patient II-8).
Our pedigree, with the other two already described and genetically proved, as well as several others currently collected in Europe and North America,20 will soon permit an identification of the CADASIL gene. This major step will provide an important advance in our knowledge of the genetics of not only cerebrovascular disease, but also familial migraine and inherited bipolar or monopolar depressive psychosis. Finally, the description of this particular phenotype of CADASIL will permit neurologists to recognise this condition in their patients, together with the description of other phenotypes. This description will permit the real frequency of CADASIL to be determined more accurately. 
